Emergent BioSolutions receives contract option valued at $16.7M

Emergent BioSolutions (EBS) announced that the Biomedical Advanced Research and Development Authority executed a contract modification for the second option period, valued at approximately $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga. Ebanga is indicated for the treatment of infection caused by Zaire Ebola virus. The existing 10-year contract consists of a base period of performance with two option periods for advanced development valued at approximately $118 million, and option periods for procurement of Ebanga treatment over five years valued at up to $583 million. Under the terms of the contract, Emergent will complete activities to advance the development of Ebanga through post-licensure commitments. These activities include manufacturing scale-up, transferring manufacturing technology, and completing stability studies, as well as the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration.